Case Presentation: Management of ICH in the Anticoagulated Patient Using Specific Reversal Therapy: Importance of Timing

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Real World Data and the Management of Intracranial Hemorrhages (ICH) in Anticoagulated Patients

Case Presentation: Management of ICH in the Anticoagulated Patient Using Specific Reversal Therapy: Importance of Timing

ReachMD Healthcare Image
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
1.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
  • Overview

    This enduring activity was originally presented as a satellite symposium which was held during the 9th European Stroke Organisation Conference (ESOC) in Munich, Germany, in May 2023.

    As the utilization of direct oral anticoagulants (DOACs) increases, there is a parallel increase in major bleeding events, especially intracranial hemorrhages (ICH), requiring hospitalization. Clinicians are not recognizing or distinguishing major from minor bleeding or appropriately employing emergent options to manage major bleeding. Recent solutions for DOAC-related life-threatening bleeding are under-recognized and under-utilized solutions for patients with these life-threatening emergencies. Recently, nationally recognized guidelines have provided clear direction for managing these major bleeding events. As data emerges regarding new approaches to therapy, clinicians need to be aware of these new and effective approaches and assess the benefits and risks associated with each of these approaches. This program focuses on managing ICHs, addresses patient treatment approaches, and distills essential information for everyday clinical practice.

  • Target Audience

    This activity has been designed to meet the educational needs of the interprofessional team, including neurologists, neurointensivists, critical care specialists, emergency medicine, clinical cardiologists, hospital medicine, radiologists, neurosurgery, nurse practitioners, physician assistants, nurses, pharmacists as well as other clinicians involved in the management of patients with intracranial hemorrhages (ICH).

  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    1. Employ appropriate treatment management strategies to address the critical clinical aspects of ICH and hematoma expansion
    2. Explain when and how to initiate appropriate reversal agents in ICH bleeds
    3. Discuss the need to develop and implement protocols and local care pathways based on existing evidence-based medicine guidelines to improve the management of ICH bleeds
  • Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change. 

  • Faculty Disclosure of Commercial Relationships

    Disclosure Policy
    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs. 

    The following faculty have disclosed:

    Natalie Kreitzer, MD, MS,  faculty for this educational event, is a contracted researcher for the HeadSMART program by BrainBox; is a speaker for Alexion, an unaffiliated neurotrauma consultant for the National Football League; and a consultant for Entegrion.   

    Adrian R. Parry-Jones, FRCP, PhD, faculty for this educational event, has received consulting fees from AstraZeneca.

    David Seiffge, MD, faculty for this educational event, has received research funding from AstraZeneca. 

  • Planners and Managers Disclosure List

    The following planners/reviewers/managers have disclosed:

    W. Brian Gibler, MD, FACEP, FACC, FAHA, planner for this educational event, is a board member/shareholder for Entegrion, Inc., and EMCREG-International; and is an advisor for Entegrion, Inc.   

    William Mencia, MD, FACEHP, CHCP, reviewer for this educational event, has no relevant financial relationships with ineligible companies.

    TotalCME, Inc. planners and managers have no relevant commercial relationships to disclose.

    All the relevant financial relationships for these individuals have been mitigated.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • Acknowledgment

    This activity is supported by an independent educational grant from AstraZeneca. 

    Jointly provided by Global Learning Collaborative (GLC), EMCREG-International, and TotalCME, Inc.

  • Fee Statement

    This activity is FREE to all participants.

  • Instructions for Completion

    During the period 06/20/2023 through 06/20/2024, registered participants wishing to receive continuing education credit for this activity must follow these steps:

    1. Read the learning objectives and faculty disclosures.
    2. Answer a pre-program question.
    3. View the program.
    4. Complete the post-test with a score of 100%. 
    5. Complete activity evaluation.
    6. Apply for credit and either bank your credits or print your certificate.

    For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule13 Jun 2024